A sirolimus drug-eluting balloon performed similarly to a usual care strategy (mostly drug-eluting stents and balloon angioplasty used in fewer cases) in patients with coronary in-stent restenosis ...

Purpose: The mechanism of action and pharmacokinetics of sirolimus when used as part of a drug-eluting stent (DES) and the efficacy and cost of using DESs versus bare-metal stents are discussed.

Scripps Clinic interventional cardiologist Paul Teirstein, M.D., became the first in Southern California to use a newly approved drug-coated balloon to clear a clogged stent that previously had been ...

A new drug-eluting balloon can perform just as well as the standard treatment for patients with coronary in-stent restenosis (ISR) undergoing repeated percutaneous coronary intervention (PCI). These ...

Please provide your email address to receive an email when new articles are posted on . A sirolimus-eluting balloon was noninferior to drug-eluting stents in treating de novo coronary lesions. The ...

In the largest randomized clinical trial and first of its kind to date in the United States, a team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) assessed the efficacy and ...

Reflow Medical announced the first six-month clinical results from a study of its Spur Elute sirolimus-eluting retrievable ...

Reflow Medical, Inc., a leading developer of innovative devices for treating complex cardiovascular disease, announces the presentation of the first six-month clinical results from the DEEPER CORONARY ...

Please provide your email address to receive an email when new articles are posted on . A paclitaxel-coated balloon bested conventional angioplasty in treating coronary in-stent restenosis. The coated ...

A new drug-eluting balloon can perform just as well as the standard treatment for patients with coronary in-stent restenosis (ISR) undergoing repeated percutaneous coronary intervention (PCI). These ...